Regorafenib
RU021212I
Phase 2 small_molecule terminated
Quick answer
Regorafenib for Adenocarcinoma of the Gastroesophageal Junction is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- UNITED THERAPEUTICS Corp
- Indication
- Adenocarcinoma of the Gastroesophageal Junction
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated